Analytical Data
-
Gene name
IL-13 R alpha 1/IL13RA1
- Application
-
Alternative Names
CD213A1; CD213-A1; IL13R-A1; IL13-RA1; IL13R-A; NR4; CT19; Cancer/testis antigen 19
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O09030
-
Expression Region
Glu28~Cys171
-
Molecular Weight
19kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-13 receptor alpha 1 (IL13RA1) is a key component of the interleukin-13 (IL-13) receptor complex, which plays a crucial role in regulating immune responses, particularly in allergic reactions and asthma. IL-13, a cytokine secreted predominantly by Th2 cells, binds to IL13RA1 to initiate signaling pathways that influence various cellular processes, including inflammation, tissue remodeling, and fibrosis. Research into IL13RA1 has garnered significant attention due to its implications in various diseases, particularly those involving excessive Th2-mediated responses, such as asthma, rhinitis, and other allergic conditions. The recombinant expression of IL13RA1 protein allows for detailed studies of its functional roles and mechanisms, providing critical insights into its potential as a therapeutic target. Understanding how IL13RA1 interacts with IL-13 and other receptors can lead to the development of novel interventions to modulate immune responses, thereby improving outcomes for patients suffering from Th2-dominated ailments. Additionally, the characterization of this receptor may contribute to the broader understanding of cytokine receptor biology and facilitate the advancement of biologic therapies aiming to inhibit pathogenic signaling pathways involved in chronic inflammatory diseases. As a result, the study of IL13RA1 and its recombinant protein forms is a vital area of research with promising implications for future therapeutic strategies.
